[(2R)-3-hydroxy-2-oxoniopropyl] 2-(trimethylazaniumyl)ethyl phosphate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [(2R)-3-hydroxy-2-oxoniopropyl] 2-(trimethylazaniumyl)ethyl phosphate
• 化学式: C8H21NO6P+
• 分子量: 258.23
• InChiKey: SUHOQUVVVLNYQR-MRVPVSSYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  96.2
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  、 [(2R)-3-hydroxy-2-oxoniopropyl] 2-(trimethylazaniumyl)ethyl phosphate 、 胆固醇 、 [(3S,4R,5R,6S)-2-[[(2R,3R,4R,5S,6R)-3-[[(3R)-3-dodecanoyloxytetradecanoyl]amino]-6-(hydroxymethyl)-5-phosphonooxy-4-[(3R)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3,6-dihydroxy-5-[[(3R)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3R)-3-hydroxytetradecanoate 在 4-羟乙基哌嗪乙磺酸 、 thiomersal 作用下， 以 氯仿 为溶剂， 反应 76.18h， 生成 n-辛基-β-D-吡喃葡萄糖苷
  参考文献：
  名称：

  IMMUNOGENIC COMPOSITION COMPRISING NEISSERIA MENIGITIDIS MACROPHAGE INFECTIVITY POTENTIATOR PROTEIN

  摘要：

  一种免疫原性组合物，包括Nm-MIP蛋白或其免疫原性部分或类似物，其中该组合物在向人类或非人类动物注射时能够引起免疫反应，并且其用途。一种制药组合物或疫苗组合物，包括Nm-MIP蛋白或其免疫原性部分或类似物。

  公开号：

  US20130230579A1

文献信息

• [EN] PHENOTHIAZINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PHÉNOTHIAZINE ET LEURS UTILISATIONS
  申请人：CAMP4 THERAPEUTICS CORP

  公开号：WO2019195789A1

  公开（公告）日：2019-10-10

  The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).

  本发明提供了吩噻嗪化合物，其制备方法，包含该化合物的药物组合物，以及在治疗各种疾病或症状中使用该化合物或组合物，例如核糖体紊乱和核糖体病，例如钻石-布莱克范贫血（DBA）。
• [EN] CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE SIGNALISATION CELLULAIRE, LEURS FORMULES ET LEURS PROCÉDÉS
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2017137958A1

  公开（公告）日：2017-08-17

  The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.

  本公开涉及一般细胞信号传导抑制剂，涉及式(I)的化合物、包含该化合物的组合物和制剂、以及它们的方法、过程和使用。特别是，本公开提供了CSF-1R抑制剂，它们表现出对CSF/CSF1R信号通路的持续抑制，并且毒性降低。本公开还提供了超分子组合疗法，其中CSF-1R抑制剂与一个或多个化疗剂、激酶抑制剂和免疫调节剂结合，其中每个可选地与脂质偶联。本公开还提供了一种治疗癌症、过敏、系统性红斑狼疮、肾炎、慢性阻塞性肺病和异常巨噬细胞功能或其任何组合的方法。
• [EN] SULFUR-CONTAINING PHOSPHOLIPID DERIVATIVES<br/>[FR] DERIVES PHOSPHOLIPIDIQUES CONTENANT DU SOUFRE
  申请人：IC VEC LTD

  公开号：WO2004000854A1

  公开（公告）日：2003-12-31

  The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X-Y-Z-, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula -[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

  本发明提供了一种脂质化合物，包括至少一个非极性基团和一个极性基团，其中每个或至少一个非极性基团为X-Y-Z-式，其中X为烃基链，Y选自S、Se、SO2、SO和O中的至少一个，Z为可选的烃基团，其中极性基团为-[C(O)]mPHG，其中PHG为极性头基团，m为非极性基团的数量。
• [EN] SMALL MOLECULE OXIDIZERS OF PDI AND THEIR USE<br/>[FR] OXYDANTS DE LA PDI À PETITE MOLÉCULE ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2016118639A1

  公开（公告）日：2016-07-28

  The present invention provides a method for treating or ameliorating the effects of a neurodegenerative disorder in a subject in need thereof comprising administering to the subject an effective amount of a compound selected from the group consisting of combinations thereof, or an N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof. The present invention also provides a method for treating or ameliorating the effects of a condition associated with increased protein disulfide isomerase (PDI) activity and a method of modulating PDI activity in a cell. The present invention also provides compounds, salts, compositions and kits useful for the provided methods.

  本发明提供了一种治疗或改善需要的受试者神经退行性疾病影响的方法，包括向受试者施用所选化合物组合中的有效量，或其N-氧化物、结晶形式、水合物或药用可接受盐。本发明还提供了一种治疗或改善与增加蛋白二硫键异构酶（PDI）活性相关的病症的方法，以及调节细胞中PDI活性的方法。本发明还提供了用于所述方法的化合物、盐、组合物和试剂盒。
• [EN] NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF<br/>[FR] PETITES CELLULES MODULANT LE PDI NEUROPROTECTEUR ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2020113222A1

  公开（公告）日：2020-06-04

  The present disclosure provides, inter alia, compounds and compositions having the formula (I) as defined herein. Methods of using and making such compounds and compositions are also provided. The present disclosure further provides screening methods, including detectable probes as well as diagnostic methods and methods for monitoring the progress of a disease, such as a neurodegenerative disease.

  本公开提供具有以下式(I)所定义的化合物和组合物，等等。还提供使用和制备这种化合物和组合物的方法。本公开还提供筛选方法，包括可检测的探针，以及诊断方法和监测疾病进展的方法，如神经退行性疾病。